2848 J . Org. Chem., Vol. 66, No. 8, 2001
Deiters and Hoppe
5.84 (m, 1H), 6.96 (d, J ) 6.5 Hz, 1H).13C NMR (75 MHz,
CDCl3): δ 23.2/23.9/25.5, 26.7, 30.8, 32.3, 40.0, 48.0, 60.1/60.9,
76.1/76.4, 95.2/96.1, 112.7/112.8, 114.3, 133.9/134.0, 139.9,
149.3/150.1. IR (neat, cm-1): 1716 (CdO). MS (EI): m/z 293
[0.5, M+], 278 [4, (M - CH3)+]. Anal. Calcd for C17H27NO3
(293.40): C, 69.59; H, 9.28; N, 4.77. Found: C, 69.19; H, 9.21;
N, 4.79. In the other cyclization reactions, depicted in Table
1, 50-100 mg of 7e were used.
[1Z,2(1R,2R)]-1-(Tr im eth ylsilyl)-2-(2-vin ylcyclop en tyl)-
eth en yl 2,2,4,4-Tetr a m eth yl-1,3-oxa zolid in e-3-ca r boxy-
la te (13c). According to the typical procedure for the enantio-
selective cyclization-substitution sequence, 7e (100 mg, 0.30
mmol, 1.0 equiv) was treated with (-)-sparteine (316 mg, 1.35
mmol, 4.5 equiv), n-BuLi (0.75 mL, 1.20 mmol, 4.0 equiv, 1.6
M solution in hexane), and TMSCl (163 mg, 1.50 mmol, 5.0
equiv) in toluene (4 mL) at -90 °C. The described workup
procedure and a subsequent purification of the crude product
by flash chromatography on silica gel (ether/pentane 1:5)
furnished 13c in 84% yield (92 mg) as a colorless liquid. The
enantiomeric excess was determined to 80% after desilylation
pentane (4 × 20 mL), and the combined organic layers were
dried with MgSO4. After evaporation of the solvents, the crude
product was purified by flash chromatography on silica gel
(pentane). The alkyne 16 (98 mg, 65%) was obtained as a
colorless, strongly smelling liquid. tR ) 9.0 min (HP1701). Rf
) 0.29 (pentane). [R]20D ) +24.2 (c ) 1.43, pentane).44 1H NMR
(300 MHz, CDCl3): δ 1.10 (t, J ) 7.5 Hz, 3H), 1.15-1.90 (m,
6H); 2.15 (dq, J ) 7.5 Hz, J ) 2.4 Hz, 2H), 2.42-2.57 (m, 1H),
2.70-2.86 (m, 1H), 4.96-5.09 (m, 2H), 5.91-6.04 (m, 1 H).
13C NMR (75 MHz, CDCl3): δ 12.5, 14.1, 23.1, 27.7, 33.1, 36.1,
47.9, 80.6, 84.2, 114.0, 140.5. MS (EI): m/z 148 [2%, M+], 133
[25%, (M - CH3)+]. HRMS calcd for C11H16 (148.24): 148.1251
(M+). Found: 148.1214 (M+).
(+)-3,4-Dih yd r om u ltifid en e (17). Lindlar’s catalyst (5%
Pd/CaCO3/Pb, 30 mg) was placed in a 50 mL round-bottom
flask and was flushed three times with H2. Then, pentane (25
mL), quinoline (2 drops), and 16 (100 mg, 0.68 mmol, 80% ee)
were added, and the suspension was strirred under a balloon
pressurized with hydrogen. After 3 h a complete conversion
was detected by GLC. Filtration through silica gel and removal
of the solvent in vacuo furnished the crude product, which was
purified by flash chromatography on silica gel (pentane)
yielding (+)-17 (78 mg, 76%). The analytical data were
to 10. 13c. tR ) 20.3 min (HP1701). Rf ) 0.60 (ether/pentane
1
1:5). [R]20 ) +28.2 (c ) 1.85, CHCl3, 80% ee). H NMR (300
D
MHz, CDCl3): δ 0.12 (s, 9H), 1.42/1.56 (s, 12H), 1.50-1.93 (m,
6H), 2.54-2.64 (m, 1H), 2.90-3.05 (m, 1 H), 3.74 (s, 2H), 4.90-
identical with those reported in the literature.21a [R]20
)
D
+50.0, [R]20 ) +52.0 (c ) 0.39, pentane, corrected to 100%
5.01 (m, 2H), 5.27 (d, 1 H, J ) 9.3 Hz), 5.66-5.82 (m, 1H). 13
C
D
ee).44 These optical rotations agree well with the literature
NMR (75 MHz, CDCl3): δ -0.9, 23.2, 23.9/25.0/25.1/26.4, 30.6,
31.5, 40.2, 47.7, 59.6/60.5, 76.0/76.2, 94.7/95.7, 113.9, 131.5,
139.7, 151.0, 153.9. IR (neat, cm-1): 1701 (CdO). MS (EI): m/z
value: [R]20 ) +55.8 (c ) 2.56, pentane, 100% ee).21a
D
(1R,2E,7E)-9-Ch lor o-1-(t r im et h ylsilyl)-n on a -2,7-d ie-
n yl 2,2,4,4-Tetr am eth yl-1,3-oxazolidin e-3-car boxylate (18).
The chloride 7e (100 mg, 0.30 mmol, 1.0 equiv), (-)-sparteine
(106 mg, 0.45 mmol, 1.5 equiv), and TMSCl (49 mg, 0.45 mmol,
1.5 equiv) were dissolved in toluene (4 mL), cooled to -78 °C,
and treated with n-BuLi (0.29 mL. 0.45 mmol, 1.5 equiv, 1.6
M solution in hexane). After stirring for 90 min at this
temperature, CH3OH (0.5 mL) and sat. NH4Cl (aq, 0.5 mL)
were added, the reaction mixture was warmed to room
temperature and was poured into Et2O (70 mL). After drying
with MgSO4 and evaporation of the solvents, the crude product
was purified by flash chromatography on silica gel (ether/
pentane 1:5) yielding 18 as colorless liquid (85 mg, 70%). The
365 [6%, M+], 350 [30%, (M - CH3)+]. Anal. Calcd for C20H35
-
NO3Si (365.58): C, 65.71; H, 9.65; N, 3.83. Found: C, 65.64;
H, 9.96; N, 4.18.
Typ ica l P r oced u r e for th e Lith ia tion a n d Su bstitu tion
of 8. [1Z,2(1R,2R)]-1-(Tr im eth ylsta n n yl)-2-(2-vin ylcyclo-
p en t yl)et h en yl 2,2,4,4-Tet r a m et h yl-1,3-oxa zolid in e-3-
ca r boxyla te (13d ). The cyclopentane 8 (38 mg, 0.13 mmol,
1.0 equiv, 70% ee) and TMEDA (18 mg, 0.16 mmol, 1.2 equiv)
were dissolved in THF (3 mL) and cooled to -78 °C. n-BuLi
(0.09 mL, 0.14 mmol, 1.1 equiv, 1.6 M solution in hexane) was
injected slowly and after stirring for 1 h Me3SnCl (0.26 mL,
0.26 mmol, 2.0 equiv, 1 M solution in hexane) was added. The
reaction was stirred for further 90 min and was subsequently
quenched by addition of CH3OH (0.5 mL) and sat. NH4Cl (aq,
0.5 mL). After warming up the reaction mixture to room
temperature, it was poured into Et2O (70 mL) and dried
(MgSO4), and the solvents were removed in vacuo. The crude
product was purified by flash chromatography on silica gel
(ether/pentane 1:10 f 1:5) furnishing 13d (44 mg, 74%) as a
colorless oil and 7 mg (18%) of the substrate 8. tR ) 18.64 min
1
enantiomeric excess was determined to 56% by a H NMR shift
experiment with 18 (20 mg) and Eu(hfc)3 (40 mg) in CDCl3
(0.7 mL). Here, the Si(CH3)3 signal splits to two new signals
at δA 0.39 ppm* and δB 0.65 ppm. tR ) 20.9 min (HP1). Rf )
0.30 (ether/pentane 1:5). [R]20D ) +11.7 (c ) 0.73, CHCl3, 56%
ee). 1H NMR (300 MHz, CDCl3): δ 0.05 (s, 9H), 1.31-1.59 (m,
14H), 1.97-2.09 (m, 4H), 3.71 (s, 2H), 3.99 (dd, J ) 6.9 Hz, J
) 0.7 Hz, 2H), 5.03 (d, J ) 5.0 Hz, 1H), 5.42-5.78 (m, 4H).13
C
(HP1). Rf ) 0.57 (ether/pentane 2:5). [R]20 ) +7.1 (c ) 0.49,
NMR (75 MHz, CDCl3): δ -3.6, 24.1/24.3/25.4/26.6/26.9, 28.6,
31.3, 31.8, 45.3, 59.5/60.8, 70.3, 76.2/76.4, 94.7/96.0, 126.3,
127.7, 128.8, 135.7, 152.8. IR (neat, cm-1): 1697 (CdO). MS
(EI): m/z ) 366 [40%, (M - Cl)+]. Anal. Calcd for C20H36ClNO3-
Si (402.04): C, 59.75; H, 9.02; N, 3.48. Found: C, 59.65; H,
9.05; N, 3.74. 18 has also been synthesized by injection of
TMSCl 15 min (22%, 46% ee) and 30 min (13%, 34% ee) after
addition of n-BuLi.
D
CHCl3).44 1H NMR (300 MHz, CDCl3): δ 0.13 (s, 9H), 1.42/
1.56 (s, 12H), 1.50-1.93 (m, 6H), 2.54-2.67 (m, 1H), 3.08-
3.25 (m, 1H), 3.75 (s, 2H), 4.81 (d, J ) 6.4 Hz, 1H), 4.91-5.02
(m, 2H), 5.69-5.84 (m, 1H). 13C NMR (75 MHz, CDCl3): δ
-6.5, 23.3, 24.0/25.1/25.4/26.6/26.7, 30.8, 32.4, 41.0, 48.0, 59.9/
60.8, 76.2, 95.0/96.0, 114.0, 126.4/126.6, 140.2, 151.5/152.2,
154.1. IR (neat, cm-1): 1680 (CdO). MS (EI): m/z 442 [67,
(M(120Sn) - CH3)+], 440 [48, (M(118Sn) - CH3)+], 438 [27, (M(116
-
(1R)-1-(Tr im eth ylsilyl)n on yl 2,2,4,4-Tetr a m eth yl-1,3-
oxa zolid in e-3-ca r boxyla te ((R)-19). The silane 18 (47 mg,
0.12 mmol, 1.0 equiv, 56% ee), the hydrogenation catalyst (100
mg, 10% Pd on charcoal), and sodium acetate (100 mg, 1.20
mmol, 10.0 equiv) were suspended in CH3OH (10 mL). After
stirring for 6 h under a balloon pressurized with hydrogen,
the reaction mixture was filtered over silica gel. Without
Sn) - CH3)+]. Anal. Calcd for C20H35NO3Sn (456.19): C, 52.66;
H, 7.73; N, 3.07. Found: C, 52.96; H, 8.12; N, 3.32.
(1R,2R)-1-(Bu t-1-yn yl)-2-vin ylcyclop en ta n e (16). The
cyclopentane 8 (300 mg, 1.02 mmol, 1.0 equiv, 80% ee) and
TMEDA (357 mg, 3.07 mmol, 3.0 equiv) were dissolved in THF
(8 mL) and cooled to -78 °C. Then n-BuLi (1.92 mL, 3.07
mmol, 3.0 equiv, 1.6 M solution in hexane) was added, and
the reaction mixture was stirred for 90 min at -78 °C before
it was warmed to room-temperature After stirring for 2.5 h at
this temperature, the solution was cooled to 0 °C and treated
with EtI (638 mg, 4.09 mmol, 4.0 equiv). The reaction mixture
was stirred for 12 h at 40 °C and then cooled to ambient
temperature, and sat. NaHCO3 (aq, 2 mL) was injected. The
layers were separated, the aqueous phase was extracted with
purification (R)-19 was obtained in 90% yield (40 mg). [R]20
) -3.9 (c ) 0.26, CHCl3, 55% op).
D
(1S)-1-Tr im eth ylsilyl-n on yl 2,2,4,4-Tetr a m eth yl-1,3-ox-
a zolid in e-3-ca r boxyla te ((S)-19). The carbamate 21 (300
mg, 1.0 mmol, 1.0 equiv) and (-)-sparteine (469 mg, 2.0 mmol,
2.0 equiv) were dissolved in Et2O and cooled to -78 °C. After
slowly addition of s-BuLi (1.3 mL, 1.50 mmol, 1.5 equiv, 1.15
M solution in hexane/cyclohexane) and stirring for 4 h at this
temperature, TMSCl (326 mg, 3.0 mmol, 3.0 equiv) was
injected and the reaction mixture was allowed to warm to room
temperature overnight. Sat. NH4Cl (aq, 3 mL) was added, the
layers were separated, and the aqueous phase was extracted
(44) The enantiomeric excess has not been determined; since 12‚9
is configuratively stable, the enantiomeric excess in the substitution
product should be the same like in the substrate 8.